Back to top
more

Emergent Biosolutions (EBS)

(Delayed Data from NYSE)

$9.20 USD

9.20
1,564,012

+0.24 (2.68%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $11.01 +1.81 (19.67%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks News

Emergent (EBS) Gets Extra $23M for COVID-19 Vaccine Production

Emergent (EBS) receives additional $23 million from BARDA to support further expansion of manufacturing capacity for Johnson & Johnson's COVID-19 vaccine.

J&J (JNJ) Gets Full Charge of Emergent COVID-19 Vaccine Plant

The U.S. government places J&J (JNJ) in charge of Emergent's Baltimore factory. The facility will cease production of AstraZeneca shots.

Why Is Emergent Biosolutions (EBS) Down 22.3% Since Last Earnings Report?

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Emergent (EBS) Beats on Q4 Earnings, Misses on Revenues

Emergent's (EBS) earnings in the fourth quarter of 2020 beat estimates while revenues miss the same. Sales of contract development and manufacturing services rise.

Vaxart (VXRT) to Report Q4 Earnings: What's in the Cards?

On Vaxart's (VXRT) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its oral COVID-19 vaccine candidate, VXA-CoV2-1.

Emergent (EBS) Posts Preliminary '20 Results, Gives 2021 View

Emergent (EBS) tightens revenue view for 2020 and expects a consistent rise in sales of contract development and manufacturing services provided to other companies.

3 Reasons Why Growth Investors Shouldn't Overlook Emergent Biosolutions (EBS)

Emergent Biosolutions (EBS) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Emergent Biosolutions (EBS) Outpaces Stock Market Gains: What You Should Know

Emergent Biosolutions (EBS) closed the most recent trading day at $97.97, moving +1.01% from the previous trading session.

Is Emergent Biosolutions (EBS) Outperforming Other Medical Stocks This Year?

Is (EBS) Outperforming Other Medical Stocks This Year?

Company News for Dec 31, 2020

Companies In The News Are: MKC, EBS, FOXA, AAPL

Emergent Biosolutions (EBS) Down 14.7% Since Last Earnings Report: Can It Rebound?

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is Emergent BioSolutions (EBS) a Good Stock to Pick Now?

Is Emergent BioSolutions (EBS) a great pick from the value investor's perspective right now? Read on to know more.

Arena (ARNA) Q3 Earnings Top, Stock Down on Eczema Study Data

Arena Pharmaceuticals (ARNA) beats bottom-line estimates for third-quarter 2020. Mid-stage atopic dermatitis study on etrasimod fails to meet primary endpoint but phase III study may start soon.

Deciphera (DCPH) Reports Narrower-Than-Expected Loss in Q3

Deciphera (DCPH) reports a narrower-than-expected loss and sales beat estimates in the third quarter of 2020.

Iovance (IOVA) Q3 Earnings Beat Estimates, Pipeline in Focus

Iovance's (IOVA) third-quarter earnings beat estimates. The company is progressing well with development of its lead pipeline candidate.

Emergent (EBS) Beats on Q3 Earnings, Tapers '20 Sales View

Emergent (EBS) beats on earnings in Q3 while revenues miss estimates. Total product sales fall year over year and the company tightens its revenue guidance. Stock slides in after-hours trading.

BioMarin (BMRN) Beats on Q3 Earnings, Lowers Sales View

BioMarin (BMRN) beats estimates for both earnings and sales in the third quarter. The company lowers its sales guidance for 2020.

Global Blood (GBT) Q3 Loss Wider Than Expected, Sales Miss

Global Blood (GBT) reports a wider-than-expected loss and misses sales estimates in the third quarter of 2020.

Amicus' (FOLD) Q3 Loss Wider Than Expected, Revenues Beat

Amicus (FOLD) reports a wider-than-expected loss but sales beat estimates in the third quarter of 2020.

Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates

Sarepta (SRPT) Q3 revenues increase year over year.

Clovis (CLVS) Q3 Earnings Top, Sales Show Coronavirus Impact

Clovis (CLVS) reports mixed third-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially. Shares plunge.

Emergent Biosolutions (EBS) Q3 Earnings Top Estimates

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 6.83% and -14.75%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zoetis' (ZTS) Q3 Earnings and Revenues Surpass Estimates

Zoetis (ZTS) beats earnings and sales estimates in the third quarter. The company raises 2020 guidance.

bluebird (BLUE) Q3 Loss Narrower Than Expected, Sales Miss

bluebird (BLUE) reports a narrower-than-expected loss and misses sales estimates in the third quarter of 2020.

Perrigo (PRGO) Q3 Earnings Beat, Revenues Miss, Stock Up

Perrigo (PRGO) reports decent third-quarter 2020 results. U.S. consumer self-care segment drives sales. Recovery in other two segments encouraging.